ANTIMICROBIAL AGENTS CHEMOTHERAPY, Feb. 2009, p. 525â€“530                                                                  Vol. 53,  2
0066-4804/09/$08.00â«¹0 doi:10.1128/AAC.00917-08
Copyright Â© 2009, American Society Microbiology. Rights Reserved.



                  Variations Amino Acid Composition Antisense
                  Peptide-Phosphorodiamidate Morpholino Oligomer
                    Affect Potency Escherichia coli Vitro
                                     VivoäŒ¤
   Brett L. Mellbye,1 Susan E. Puckett,2 Luke D. Tilley,1 Patrick L. Iversen,1 Bruce L. Geller1,2*
                                AVI BioPharma, ,1 Oregon State University,2 Corvallis, Oregon
                      Received 10 July 2008/Returned modification 24 September 2008/Accepted 7 November 2008

             potency antisense peptide-phosphorodiamidate morpholino oligomers (PPMOs) improved           varying peptide composition. antisense phosphorodiamidate morpholino oligomer (PMO) complemen-
          tary mRNA essential gene acpP  encodes acyl carrier protein required lipid
          biosynthesis) Escherichia coli conjugated 5â´• ends various cationic membrane-penetrating
          peptides. peptide repeating sequence motifs: C-N-N (motif 1), C-N (motif 2), C-N-C
          (motif 3), C cationic residue N nonpolar residue. Variations cationic residues included
          arginine, lysine, ornithine (O). Variations nonpolar residues included phenylalanine, valine,
          â?¤-alanine (B), 6-aminohexanoic acid (X). MICs PPMOs varied 0.625 >80 â?®M            3 480 â?®g/ml). potent (RX)6B-, (RXR)4XB-, (RFR)4XB-AcpP PMOs,           tested mice infected E. coli. (RXR)4XB-AcpP PMO potent           conjugates tested mice. administration 30 â?®g (1.5 mg/kg body weight) (RXR)4XB-AcpP PMO           15 min postinfection reduced CFU/ml blood 102 103 2 12 h compared numbers           water-treated controls. mice treated 30 â?®g/dose (RXR)4XB-AcpP PMO survived infection,           water-treated mice died 12 h postinfection. reduction CFU/ml blood proportional dose
          PPMO 30 300 â?®g/ml. summary, C-N-C motif effective motifs,
          arginine effective lysine ornithine, phenylalanine effective 6-aminohexanoic
          acid vitro necessarily vivo, (RXR)4XB-AcpP PMO reduced bacterial infection promoted
          survival clinically relevant doses.


  Antibiotic resistance bacteria, increasing incidence,              conjugated counterparts (7, 10). Apparently, membrane- decreasing rate discovery new antibiotics create            penetrating peptide carries cargo  antisense
need new strategies targeting bacterial components               oligomer) outer membrane gram-negative bac-
antibiotic therapy. Genomics created attractive oppor-               teria, traverses plasma membrane tunity target specific genes inhibition use                unknown mechanism.
antisense oligomers silence essential genes.                                Membrane-penetrating peptides diverse sequences,
  Synthetic antisense oligomers DNA mimics bind                    cationic amphipathic. Previous investiga- target RNA complementary base pairing.                      tions suggest repeated peptide motif cationic
antisense oligomers added pure bacterial cultures,                   residue followed nonpolar residues shown decrease levels expression                important feature efficient membrane penetration
reporter genes luciferase (5, 7), activate endogenous               (25).
genes â?¤-galactosidase (7), inhibit growth tar-                   Antisense oligomers conjugated peptides (KFF)3
geting essential genes RNA (9, 10, 11, 14, 23, 28).                   (RFF)3 targeted essential gene products potent
addition, antisense oligomers reduce infection increase
                                                                            growth inhibitors E. coli, Salmonella enterica serovar Typhi- survival mice infected Escherichia coli (8, 21,
                                                                            murium, Staphylococcus aureus, Mycobacterium smegmatis, 22).
                                                                            Klebsiella pneumoniae (10, 13, 14, 23). antisense pep-
  Antisense oligomers require assistance gain entry                                                                             tide-oligomers variations peptide sequences bacterial cells molecular weight polar
                                                                            screened efficacies gram-positive bacte-
characteristics. Recently, antisense oligomers                                                                             rium S. aureus (17), effects variations conjugated membrane-penetrating peptides. Peptide-oli-
gomer conjugates significantly effective inhibit-               gram-negative bacterium E. coli reported (10, 23).
ing expression specific targets non-                 reports effects                                                                             variations peptide sequences antisense peptide-
                                                                            oligomers animal models bacterial infection.
  * Corresponding author. Mailing address: Department Microbi-              study described report, E. coli used ology, 220 Nash Hall, Oregon State University, Corvallis, 97331-
                                                                            compare efficacies vitro vivo antisense pep-
3804. Phone: (541) 737-1845. Fax: (541) 737-0496. E-mail: gellerb
@orst.edu.                                                                  tide-phosphorodiamidate morpholino oligomers (PPMOs)
  äŒ¤
    Published ahead print 17 November 2008.                           vary amino acid sequences.

                                                                      525
 526       MELLBYE ET AL.                                                                                                         ANTIMICROB. AGENTS CHEMOTHER.

                        MATERIALS METHODS                                              TABLE 1. MICs peptide-AcpP11 PMO conjugates pure
   Bacterial strains. Wild-type strain E. coli K-12 W3110 used exper-                             cultures E. coli
iments. Liquid cultures grown Mueller-Hinton II broth  MIC                                                                                 MIC
assays) LB broth  preparation inoculum mice).                       Motif PMO                   Conjugated peptide
   MICs. MICs determined microdilution method (4). control                                                                           â?®M          â?®g/ml
nonspecific toxicity, peptide conjugated second phosphoro-
diamidate morpholino oligomer (PMO) base sequence                Motif 1 (C-N-N)
complementary gene E. coli. cases, MIC control PPMO       05-0198                      RFFXB                              â¬Ž80       â¬Ž360 limit measurement, 80 â?®M.                                  05-0197                      RFFRFFXB                            20         99
   PMO. PPMOs synthesized AVI BioPharma (Corvallis,                  05-0200                      RFFRFFRFFRXB                         2.5       14
scribed previously (23). base sequence AcpP PMO 5â¬˜-CTTCGAT              05-0653                      DRFDFDRDFDFDRDFDFD                   5         28
AGTG-3â¬˜, complementary bases 1153197 1153207 E. coli                                           RXBa
W3110 genomic map (NCBI accession number AP009048). target sequence                23-248                      RXXRXXRXXB                          20        102 immediately 3â¬˜ start codon. rationale length position     06-0199                     KFFKFFKFFKXB                        10         54 PMO target mRNA characterized previously (5). PMO             06-0064                     RBBRBBRBBRXB                       â¬Ž80       â¬Ž408
sequence shown inhibit growth E. coli pure cultures (5, 8,       06-0079                     RVVRVVRVVRXB                       â¬Ž80       â¬Ž422
23), infected tissue culture (23), mouse models infection (8, 22). base     06-0082                     OFFOFFOFFOXB                       â¬Ž80       â¬Ž431
sequence nonsensical control PMOs 5â¬˜-TCTCAGATGGT-3â¬˜. non-
sensical (scrambled) sequence random sequence 11 bases used         Motif 2 (C-N) AcpP PMO previously shown inhibit growth E.         06-0067                      RXRXB                              â¬Ž80       â¬Ž358
coli (5, 8, 23, 24).                                                                  06-0070                      RXRXRXRXB                           80        401
   Mouse experiments. mice infected treated PPMOs            06-0073                      RXRXRXRXRXRXB                        1.25       6.9
described previously (22). Briefly, groups mice infected     06-0761                      KXKXKXKXKXKXB                      â¬Ž80       â¬Ž430 intraperitoneal injection E. coli W3110. mice treated intra-       06-0762                      OXOXOXOXOXOXB                      â¬Ž80       â¬Ž424
peritoneal injection 15 min 12 h postinfection. Blood collected 2,
6, 12, 24, 48 h postinfection; diluted; plated determine numbers      Motif 3 (C-N-C) viable bacteria.                                                                   06-0076                      RXRRXRRXRRXRXB                       1.25          7.2
   animal procedures approved Oregon State University Animal          06-0824                      KXKKXKKXKKXKXB                      20           111
Care Use Committee complied state federal laws.                  06-0763                      OXOOXOOXOOXOXB                      10            54
   Statistical analysis. mean numbers CFU/ml blood standard devi-          07-0795                      RFRRFRRFRRFRXB                       0.625         3.7
ation calculated treatment group using Prism (version 4.0)           07-1119                      RXRRBRRXRRBRXB                       2.5          14
software (GraphPad Software, San Diego, CA). Survival curves analyzed Kaplan-Meier method Prism (version 4.0) software. Group means          Control (ampicillin)                                               6.7            2.5
compared transforming numbers CFU/ml log CFU/ml using                                                                                                       D,   residue follows D-isomeric form. way analysis variance, parametric methods, Kolmogorov Smirnov
normality test, Tukey-Kramer multiple comparison post test (InStat,
version 3.05, software; GraphPad Software).


                                                                                     form (RFF)3RXB (PPMO 05-0653) MIC                                   RESULTS                                            times higher equivalent L-isomeric
   Efficacies various PPMOs pure culture. Various                              form (PPMO 05-0200).
PPMOs synthesized base sequence targeting                            MIC PPMO motif 2 (C-N) motif 3 region near start codon mRNA acpP,                          (C-N-C) measured. PPMOs (RX)6B, (RXR)4XB, different peptides attached 5â¬˜ end (Table 1). pep-                       (RFR)4XB potent PPMOs (RXX)3B tide designed repeated sequence motifs:                        (RFF)3RXB. substitution lysine ornithine   C-N-N (motif 1), (ii) C-N (motif 2), (iii) C-N-C (motif 3),                   arginine PPMOs motif 2 3 reduced potency. C cationic residue N nonpolar residue.                       tandem copies RX potent tandem
cationic amino acids used arginine, lysine,                       copies RX.
ornithine (O); nonpolar amino acids used                              Mouse peritonitis. (RX)6B-AcpP PMO, (RXR)4XB- phenylalanine, valine, â?¤-alanine (B), 6-aminohex-                           AcpP PMO, (RFR)4XB-AcpP PMO tested mice
anoic acid (X).                                                                      infected E. coli. Groups mice treated various
   MIC PPMO motif 1 (C-N-N) mea-                                doses PPMOs ranging 10 300 â?®g 15 min 12 h
sured shown Table 1. Control PPMOs                           postinfection.
peptides attached PMO complementary se-                                  results (RXR)4XB-AcpP PMO quence MICs 80 â?®M (data shown). results                            potent PPMOs tested mice (compare
indicate potent PPMO peptide motif 1                          effects 30-â?®g dose PPMO shown Fig. 1A,
(RFF)3RXB, 2.5 times potent                                B, E, F, G, H). 30-â?®g dose (1.5 mg/kg body weight)
ampicillin molar basis. Furthermore, increasing num-                        (RXR)4XB-AcpP PMO significantly (P â¬? 0.001) 
ber RFF repeat units reduced MIC                            duced levels bacteria blood 98  2 h
â¬Ž32-fold â¬Ž80 2.5 â?®M. replacement arginine                             compared levels water- scrambled-sequence- lysine ornithine increased MIC 4-fold                             PPMO-treated controls. Higher doses (100 â?®g 300 â?®g) â¬Ž32-fold, respectively. substitution valine, â?¤-alanine,                       (RXR)4XB-AcpP PMO reduced CFU/ml 6-aminohexanoic acid phenylalanine increased                              blood proportionally 2.5 4 orders magnitude
MICs eightfold (compare MICs PPMOs 06-                               12 h posttreatment. mice treated 0079, 06-0064, 23-248 MIC PPMO 05-0200                               30-â?®g, 100-â?®g, 300-â?®g dose survived infection. Table 1). Interestingly, PPMO D-isomeric                             significant difference (P â¬Ž 0.05) rates survival
 VOL. 53, 2009                                                                         ANTISENSE MORPHOLINO POTENCY                 527




  FIG. 1. Bacteria blood survival mice. Groups mice (n â«½ 3 7) infected E. coli treated 15 min 12 h
postinfection (arrows) various PPMOs, scrambled-base-sequence (Scr) (RXR)4XB PPMO, ampicillin. Blood collected indicated times spread LB plates determine numbers CFU.  B) (RXR)4XB-PMO; (C D) ampicillin; (E F)
(RX)6B-PMO; (G H) (RFR)4XB-PMO. Error bars indicate standard deviations.


 group treated water treated 10        B). 30-â?®g dose (RX)6B-AcpP PMO signifi-
â?®g.                                                                  cantly (P â¬? 0.001) reduced CFU/ml blood 88  2 h
   Groups mice treated 30-â?®g, 100-â?®g, 300-â?®g       postinfection. 100-â?®g 300-â?®g doses significantly
dose ampicillin comparison results ob-        (P â¬? 0.001) reduced CFU/ml blood equally 3
tained mice treated PPMO (Fig. 1C D). Thirty-         orders magnitude times postinfection. mice treated
microgram doses ampicillin ineffective reducing           100 â?®g/dose (RX)6B-AcpP PMO survived, sig-
CFU/ml blood increasing rate survival.      nificant numbers mice did survive treatment 10 â?®g, higher doses ampicillin significantly (P â¬? 0.001) reduced     30 â?®g, 300 â?®g dose.
CFU/ml blood 3 3.5 orders magnitude           (RFR)4XB-AcpP PMO significantly reduced increased rate survival 100  48 h.                   numbers bacteria blood promoted survival (Fig.
   (RX)6B-AcpP PMO significantly reduced CFU/ml               1G H). Doses 10 â?®g 30 â?®g did significantly (P â¬Ž
blood (Fig. 1E F), potent          0.05) reduce CFU/ml blood time. Doses 100 â?®g
(RXR)4XB-AcpP PMO (compare Fig. 1E F Fig. 1A                300 â?®g significantly (P â¬? 0.01 â¬? 0.001, respectively)
 528     MELLBYE ET AL.                                                                               ANTIMICROB. AGENTS CHEMOTHER.


reduced CFU/ml blood 2 h posttreatment.            PPMOs amino acid sequence repeat similar CFU/ml blood reduced proportionally dose,          (RFF)3RXB-AcpP (repeat motif 1; Table 1), arginine supe- 300-â?®g dose showed reduction (2 3 orders          rior lysine ornithine phenylalanine superior magnitude) 2, 6, 12 h postinfection. number            valine, â?¤-alanine, 6-aminohexanoic acid. PPMOs
surviving mice proportional dose.                         repeat motifs 2 3, trends similar                                                                      motif 1, valine â?¤-alanine evaluated                          DISCUSSION                                  substitutes nonpolar residues. Unfortunately, attempts                                                                      synthesize (RF)6XB-AcpP PMO unsuccessful 
   purpose experiments increase po-            cause insoluble aqueous solution. effects tency antisense PPMOs targeted essential gene              observed antimicrobial peptides (18, 26). acpP, previously shown inhibit growth E.         role cationic chains make initial electrostatic
coli pure culture infected mice (22).              contact anionic moieties lipids (3, 29), results
hypothesized efficacies PPMOs increase          consistent suggestion dispersed
varying order cationic nonpolar amino acid res-           positive charge guanidinium group arginine elec-
idues repeating motif replacing arginine            trostatically interact anionic moieties lipids cationic amino acids, phenylalanine            productive manner lysine ornithine (18,
nonpolar amino acids, naturally occurring amino acids             26). superior effect phenylalanine thought nonprotein amino acids. rationale including             attributable bulkiness (19, 20).
nonprotein amino acids peptide moiety pro-              interesting result D-isomers place teolytic degradation reduced.                               L-isomers arginine phenylalanine increased MIC    Previously, Vaara Porro (25) suggested possibility        factor 2. suggests mechanism entry repeating amino acid sequence motifs (cationic-hydro-       PPMOs outer membrane E. coli receptor
phobic-hydrophobic) (cationic-hydrophobic) influ-          mediated. result consistent previous results ence membrane-penetrating characteristics peptides.           models predicted cationic amphipathic results suggest motif effective        peptides penetrate directly membrane lipids (6, 16, motif disorganizing outer membrane         29, 30).
gram-negative bacteria. experiments used com-            (RX)6B-, (RXR)4XB-, (RFR)4XB-AcpP PMOs
pletely different end point used experiments     significantly reduced infections mice. Vaara Porro (25), results spacing           (RXR)4XB-AcpP PMO reduced levels bacteremia cationic nonpolar residues does effect support       dose-dependent manner, (RX)6B-AcpP PMO  suggestion motif cationic-nonpolar-cationic        duced CFU/ml blood similar extents 100 â?®g residues slightly effective motifs        300 â?®g dose. response treatment tested.                                                              (RFR)4XB-AcpP PMO proportional dose early
   mechanisms amphipathic peptides penetrate            times treatment, reflected rate biological membranes controversial depend             survival. (RXR)4XB-AcpP PMO potent structures compositions peptides target               PPMOs tested, 100  mice survived treat-
membranes (12, 29). experiments di-              ment dose low 30 â?®g (1.5 mg/kg).
rectly address mechanism penetration, results            (RXR)4XB-AcpP PMO potent ampi-
consistent presented reports demon-         cillin. vitro MIC analysis showed molar basis,
strate importance number repeating sequence            PPMO times potent. motifs choice cationic nonpolar amino acids.       molecular weight (RXR)4XB-AcpP PMO 16 recent study, number RW sequence repeats varied         times greater ampicillin, basis weight, (15). optimal number            (RXR)4XB-AcpP PMO times potent  results RFF repeats        vitro.  mouse model infection used ineffective RFF repeats significantly          experiments, (RXR)4XB-AcpP PMO po-
creased efficacy.  RX repeats inef-         tent, weight basis. Clearly, 30 â?®g fective, RX repeats highly effective. similar         (RXR)4XB-AcpP PMO effective lowering
effect shown uptake PPMOs HeLa              CFU/ml blood promoting survival 30 â?®g cells (27). suggests length overall   ampicillin (compare Fig. 1A B Fig. 1C D). charge peptide important number         conclude (RXR)4XB-AcpP PMO potent repeats. Alternatively, effect influenced       ampicillin reducing CFU/ml blood increasing
bulkiness hydrophobicity nonpolar chains.          rate survival, model infection cause 6-aminohexanoic acid chain, presumed           used testing.
interaction hydrophobic core bilayer             (RFR)4XB-AcpP PMO lowest MIC, quite different phenylalanine. Previous results         effective PPMO vivo. reason concluded short membrane-penetrating peptides          unclear, possibility composition 
 ones used), composition amino        peat pattern natural amino acids suscep-
acids important order amino acids            tible proteolysis animals. Alternatively, (19, 20).                                                            favorable pharmacokinetics bioavailability    results vitro testing showed             PPMOs.
 VOL. 53, 2009                                                                                         ANTISENSE MORPHOLINO POTENCY                              529


   Thirty percent mice treated 300 â?®g/dose (RX)6B-                     3. Brown, K. L., R. E. W. Hancock. 2006. Cationic host defense (antimi-
                                                                                      crobial) peptides. Curr. Opin. Immunol. 18:24â€“30.
AcpP PMO died, despite having levels bacteria blood                      4. Clinical Laboratory Standards Institute. 2006. Methods dilution
comparable blood mice treated 100                             antimicrobial susceptibility tests bacteria grow aerobically, 7th ed.,
â?®g/dose, survived. results suggest                        approved standard M7-A7. Clinical Laboratory Standards Institute,
                                                                                      Wayne, PA.
(RX)6B-AcpP PMO toxic mice 300-â?®g/dose                            5. Deere, J., P. Iversen, B. L. Geller. 2005. Antisense phosphorodiami-
(â¬ƒ15 mg/kg), account lack ability                          date morpholino oligomer length target position effects gene- reduce CFU/ml blood compared numbers                            specific inhibition Escherichia coli. Antimicrob. Agents Chemother.
                                                                                      49:249â€“255. group treated 100 â?®g/dose. Similar PPMOs                      6. Dennison, S. R., J. Wallace, F. Harris, D.  Phoenix. 2005. Amphiphilic
RX repeating motif toxic tissue culture (27).                         â?£-helical antimicrobial peptides structure/function relationships.
                                                                                      Protein Pept. Lett. 12:31â€“39.
apparent toxicity mice likely caused peptide moiety                   7. Geller, B. L., J. D. Deere, D.  Stein, D. Kroeker, H. M. Moulton, P. L. conjugate, PMO attached pep-                            Iversen. 2003. Inhibition gene expression Escherichia coli antisense
tide nontoxic doses (8).                                                  phosphorodiamidate morpholino oligomers. Antimicrob. Agents Che-
                                                                                      mother. 47:3233â€“3239.
   (RX)6B-AcpP PMO toxic 15 mg/kg, rela-                         8. Geller, B. L., J. Deere, L. Tilley, P. L. Iversen. 2005. Antisense phos-
tively short time death (12 h) bit unusual suggests                     phorodiamidate morpholino oligomer inhibits viability Escherichia coli rapid event lipopolysaccharide-induced cytokine cas-                        pure culture mouse peritonitis. J. Antimicrob. Chemother. 55:983â€“
                                                                                      988.
cade. Alternatively, plausible arginines (RX)6                   9. Good, L., P. E. Nielsen. 1998. Inhibition translation bacterial converted nitric oxide synthase.                         growth peptide nucleic acid targeted ribosomal RNA. Proc. Natl. Acad.
                                                                                      Sci. USA 95:2073â€“2076.
lead critical events lung, heart, brain,                                                                                   10. Good, L., S. K. Awasthi, R. Dryselius, O. Larsson, P. E. Nielsen. 2001. lead death 12 h.                                                          Bacterial antisense effects peptide-PNA conjugates. Nat. Biotechnol. 19:
   apparent short-term, gross toxicity                          360â€“364.
                                                                                  11. Gruegelsiepe, H., O. Brandt, R. K. Hartmann. 2006. Antisense inhibi-
(RXR)4XB-AcpP PMO, highest dose tested (300                               tion RNase P: mechanistic aspects application live bacteria. J. Biol.
â?®g [15 mg/kg]), determined 100  survival rate                            Chem. 281:30613â€“30620.
mice treatment group. Previous results shown                    12. Henriques, S. T., M. N. Melo, M.  R. B. Castanho. 2006. Cell-pene-
                                                                                      trating peptides antimicrobial peptides: different  Bio- (RXR)4XB PMO causes significant toxicity 150 mg/kg                            chem. J. 399:1â€“7.
rats 50  lethal dose 210 mg/kg (2).                   13. Kulyte, , N. Nekhotiaeva, S. K. Awasthi, L. Good. 2005. Inhibition safety values converted mice use                           Mycobacterium smegmatis gene expression growth using antisense pep-
                                                                                      tide nucleic acids. J. Mol. Microbiol. Biotechnol. 9:101â€“109.
conventional surface area calculations (24), toxicity mice                 14. Kurupati, P., K. S. W. Tan, G. Kumarasinghe, C. L. Poh. 2007. Inhibi- translate 300 mg/kg.  estimated ther-                         tion gene expression growth antisense peptide nucleic acids                                                                                       multiresistant â?¤-lactamase-producing Klebsiella pneumonia strain. Antimi-
apeutic index (50  lethal dose/50  effective dose)                             crob. Agents Chemother. 51:805â€“811.
(RXR)4XB-AcpP PMO greater 200 (300 mg/kg/                             15. Liu, ,  Brady,  Young, B. Rasimick, K. Chen, C. Zhou, N. R.
1.5 mg/kg).                                                                           Kallenbach. 2007. Length effects antimicrobial peptides (RW)n
                                                                                      series. Antimicrob. Agents Chemother. 51:597â€“603.
   Recently, (RXR)4 efficiently deliver                         16. Maloy, W. L., U. P. Kari. 1995. Structure-activity studies magainins
PMOs eukaryotic cell plasma membrane                                 host defense peptides. Biopolymers 37:105â€“122.
HeLa CHO cells (1). mechanism entry                            17. Nekhotiaeva, N., S. K. Awasthi, P. E. Nielsen, L. Good. 2004. Inhibition
                                                                                      Staphylococcus aureus gene expression growth using antisense peptide eukaryotic cell plasma membrane apparently                              nucleic acids. Mol. Ther. 10:252â€“259.
mediated binding proteoglycan, mechanism sub-                        18. Shafer, W. M., F. Hubalek, M. Huang, J. Pohl. 1996. Bactericidal
                                                                                      activity synthetic peptide (CG 117-136) human lysosomal cathep-
sequent transit internal membranes nu-                            sin G dependent arginine content. Infect. Immun. 64:4842â€“4845.
cleus unknown. ability (RXR)4XB mediate                          19. Strom, M. B., B. E. Haug, O. Rekdal, M. L. Skar, W. Stensen, J. S.
entry PMOs eukaryotic prokaryotic cells                              Svendsen. 2003. Important structural features 15-residue lactoferricin
                                                                                      derivatives methods improvement antimicrobial activity. Biochem.
suggests antibacterial PPMOs designed use                           Cell Biol. 80:65â€“74. intracellular bacteria.  preliminary data                       20. Strom, M. B., O. Rekdal, J. S. Svendsen. 2002. Antimicrobial activity dicate (RXR)4XB PMOs targeted specific essential                              short arginine- tryptophan-rich peptides. J. Pept. Sci. 8:431â€“437.
                                                                                  21. Tan, X.-X., J. K. Actor, Y. Chen. 2005. Peptide nucleic acid antisense
genes significantly reduce intracellular Salmonella, Chlamydia,                       oligomer therapeutic strategy bacterial infection: proof prin- Mycobacterium levels (G. Mitev B. L. Geller, unpub-                           ciple using mouse intraperitoneal infection. Antimicrob. Agents Chemother.
lished data).                                                                         49:3203â€“3207.
                                                                                  22. Tilley, L. D., B. L. Mellbye, S. E. Puckett, P. L. Iversen, B. L. Geller.
                                                                                      2007. Antisense peptide-phosphorodiamidate morpholino oligomer conju-
                        ACKNOWLEDGMENTS                                               gate: dose-response mice infected Escherichia coli. J. Antimicrob.
                                                                                      Chemother. 59:66â€“73.
  thank entire chemistry department AVI BioPharma                   23. Tilley, L. D., O. S. Hine, J.  Kellogg, J. N. Hassinger, D. D. Weller, P. L.
making purifying PPMOs. thank Alix Gitelman advice                     Iversen, B. L. Geller. 2006. Gene-specific effects antisense phos- statistical analysis.                                                              phorodiamidate morpholino oligomer-peptide conjugates Escherichia
  work funded AVI BioPharma.                                              coli Salmonella enterica serovar Typhimurium pure culture   Bruce Geller employed AVI BioPharma Oregon                          tissue culture. Antimicrob. Agents Chemother. 50:2789â€“2796.
                                                                                  24. U.S. Food Drug Administration, Center Drug Evaluation 
State University.                                                                     search. 2008. Dose calculator convert animal dose human equivalent
                                                                                      dose. Center Drug Evaluation Research, U.S. Food Drug Ad-
                               REFERENCES                                             ministration, Rockville MD. http://www.fda.gov/cder/cancer/animalframe
1. Abes, S., H. M. Moulton, P. Clair, P. Prevot, D. S. Youngblood, R. P. Wu,          .htm. Date accessed, 7 July 2008.
   P. L. Iversen, B. Lebleu. 2006. Vectorization morpholino oli-           25. Vaara, M., M. Porro. 1996. Group peptides act synergistically
   gomers (R-Ahx-R)4 peptide allows efficient splicing correction           hydrophobic antibiotics gram-negative enteric bacteria. Antimi-
   absence endosomolytic agents. J. Control. Release 116:304â€“313.              crob. Agents Chemother. 40:1801â€“1805.
2. Amantana, , H. M. Moulton, M. L. Cate M. 